162162

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International publication date
13 February 2003 (13.02.2003)

PCT

(10) International publication number
WO 03/011262 A1

(51) International patent classification[7]: A61K 31/00

(21) International application number: PCT/EP02/07959

(22) International filing date: 17 July 2002 (17.07.2002)

(25) Language of filing: German

(26) Language of publication: German

(30) Data relating to the priority:
101 35 815.6 23 July 2001 (23.07.2001) DE

(71) Applicant *(for all designated States except US)*: BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants *(US only)*: NIEWÖHNER, Ulrich [DE/DE]; Gartenstr. 3, 42929 Wermelskirchen (DE). BISCHOFF, Erwin [DE/DE]; Pahlkestr. 73, 42115 Wuppertal (DE). HANING, Helmut [DE/US]; 400 Morgan Lane, West Haven, CT 06516-4175 (US). RAHBAR, Afssaneh [DE/DE]; Zeppelinstr. 2A, 42781 Haan (DE). BANDEL, Tiemo-Joerg [DE/DE]; Ebersbachstr. 70a, 46145 Oberhausen (DE). BARTH, Wolfgang [DE/US]; 400 Morgan Lane, West Haven, CT 06516-4175 (US).

(74) Joint Representative: BAYER AKTIENGESELLSCHAFT; 51368 Leverkusen (DE).

(81) Designated states *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated states *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

- *As to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).*

Published:

- *Without the International Search Report and to be republished once the report has been received.*

For an explanation of the two-letter codes and the other abbreviations, reference is made to the explanations ("Guidance Notes on Codes and Abbreviations") at the beginning of each regular edition of the PCT Gazette.

As printed

(54) Title: USE OF 2-ALKOXYPHENYL-SUBSTITUTED IMIDAZOTRIAZINONES

(54) Bezeichnung: VERWENDUNG VON 2-ALKOXYPHENYL-SUBSTITUIERTEN IMIDAZOTRIAZINONEN

(57) Abstract: The invention relates to the use of known 2-phenyl substituted imidazotriazinones having short, unbranched alkyl radicals in the 9 position and cGMP-PDE-inhibiting properties for the production of medicaments to treat heart insufficiency, psoriasis, female infertility, cancer, diabetes, eye diseases such as glaucoma, disorders of stomach movement, cystic fibrosis, premature contractions, pulmonary high blood pressure, bladder diseases, prostatic hyperplasia, nitrate-induced tolerance, preeclampsia, alopecia, Parkinson's disease, pain, tinnitus or renal syndrome.

(57) Zusammenfassung: Die vorliegende Erfindung betrifft die Verwendung von bekannten 2-Phenyl-substituierten Imidazotriazinonen mit kurzen, unverzweigten Alkylresten in der 9-Position und cGMP-PDE-inhibitorischen Eigenschaften zur Herstellung von Arzneimitteln zur Behandlung von Herzinsuffizienz, Psoriasis, weiblicher Infertilität, Krebs, Diabetes, Augenerkrankungen wie Glaukom, Störungen der Magenbeweglichkeit, zystischer Fibrose, vorzeitigen Wehen, pulmonarem Bluthochdruck, Blasenerkrankungen, Prostatahyperplasie, nitrat-induzierte Toleranz, Präeklampsie, Alopecia, der Parkinson-Krankheit, Schmerz, Tinnitus oder dem renalen Syndrom.

WO 03/011262 A2